Marlene A. Jacobson

Marlene A. Jacobson

Auto-generated profile, based on publicly available information

Marlene A. Jacobson

Moulder Center for Drug Discovery Research, Temple University School of Pharmacy, Philadelphia PA 3

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2021 in Journal of General Physiology
Verified
Journal Article
Open access
PDF file
AVAlexandre G. Vouga
Alexandre G. Vouga
MRMichael E. Rockman
Michael E. Rockman
JYJiusheng Yan
Jiusheng Yan
MJMarlene A. Jacobson
Marlene A. Jacobson
BRBrad S. Rothberg
Brad S. Rothberg
Large-conductance Ca2+-activated K+ (BK) channels control a range of physiological functions, and their dysfunction is linked to human disease. We have found that the widely used drug loperamide (LOP) can inhibit activity of BK channels composed of either α-subunits (BKα channels) or α-subunits plus the auxiliary γ1-subunit (BKα/γ1 channels), and here we analyze the molecular mechanism of LOP action. LOP applied at the cytosolic side of the membrane rapidly and reversibly inhibited BK current, an effect that appeared as a decay in voltage-activated BK currents. The apparent affinity for LOP decreased with hyperpolarization in a manner consistent with LOP behaving as an inhibitor of open, activated channels. Increasing LOP concentration reduced the half-maximal activation voltage, consistent with relative stabilization of the LOP-inhibited open state. Single-channel recordings revealed that LOP did not reduce unitary BK channel current, but instead decreased BK channel open probability and mean open times. LOP elicited use-dependent inhibition, in which trains of brief depolarizing steps lead to accumulated reduction of BK current, whereas single brief depolarizing steps do not. The principal effects of LOP on BK channel gating are described by a mechanism in which LOP acts as a state-dependent pore blocker. Our results suggest that therapeutic doses of LOP may act in part by inhibiting K+ efflux through intestinal BK channels.

10 July 2019 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
MJMarlene A. Jacobson
Marlene A. Jacobson
LJLaura J. Jones
Laura J. Jones
DCDennis J. Colussi
Dennis J. Colussi
JTJacqueline C. Tanaka
Jacqueline C. Tanaka

1 October 2020 in Tetrahedron Letters
Verified
Journal Article
Closed access
EHElizabeth D. Hewlett
Elizabeth D. Hewlett
EMEdward Melenski
Edward Melenski
FQFrederick V. Qiu
Frederick V. Qiu
HLHiu T. Leung
Hiu T. Leung
MJMarlene Jacobson
Marlene Jacobson
WCWayne Childers
Wayne Childers